[{"id":"189c84d8-9170-41ee-88a7-ba2d750c2705","acronym":"PRISM-MEL-301","url":"https://clinicaltrials.gov/study/NCT06112314","created_at":"2023-11-01T15:12:45.028Z","updated_at":"2024-07-02T16:34:26.248Z","phase":"Phase 3","brief_title":"IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)","source_id_and_acronym":"NCT06112314 - PRISM-MEL-301","lead_sponsor":"Immunocore Ltd","biomarkers":" BRAF • HLA-A","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • HLA-A*02","tags":["BRAF • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdualag (nivolumab/relatlimab-rmbw) • brenetafusp (IMC-F106C) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 680","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-06-13"},{"id":"68a67f53-3f78-4080-af42-75466b7cacd6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04262466","created_at":"2021-01-18T20:42:48.114Z","updated_at":"2024-07-02T16:35:12.070Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","source_id_and_acronym":"NCT04262466","lead_sponsor":"Immunocore Ltd","biomarkers":" HLA-A • PRAME","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • Kimmtrak (tebentafusp-tebn) • brenetafusp (IMC-F106C)"],"overall_status":"Recruiting","enrollment":" Enrollment 727","initiation":"Initiation: 02/25/2020","start_date":" 02/25/2020","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-04-02"},{"id":"5fc95c78-0abd-4ca1-9e8e-6011739ca3e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04284228","created_at":"2021-01-18T20:47:52.551Z","updated_at":"2024-07-02T16:35:23.484Z","phase":"Phase 1/2","brief_title":"Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT","source_id_and_acronym":"NCT04284228","lead_sponsor":"NexImmune Inc.","biomarkers":" HLA-A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • NEXI-001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/20/2020","start_date":" 02/20/2020","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-01-15"},{"id":"d41013a9-659b-4bd4-843d-44f12482f427","acronym":"STELLA","url":"https://clinicaltrials.gov/study/NCT02475707","created_at":"2021-01-18T11:55:12.467Z","updated_at":"2024-07-02T16:35:31.622Z","phase":"Phase 1","brief_title":"Administration of Donor MultiTAA-Specific T Cells for ALL","source_id_and_acronym":"NCT02475707 - STELLA","lead_sponsor":"Baylor College of Medicine","biomarkers":" CD8 • CD4 • MME","pipe":"","alterations":" ","tags":["CD8 • CD4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MultiTAA T cell therapy"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 10/29/2019","primary_completion_date":" 10/29/2019","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-10-26"},{"id":"9eac4268-8e45-4c25-be18-2972151ca188","acronym":"","url":"https://clinicaltrials.gov/study/NCT02494167","created_at":"2021-01-18T12:01:22.240Z","updated_at":"2024-07-02T16:35:45.346Z","phase":"Phase 1","brief_title":"Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)","source_id_and_acronym":"NCT02494167","lead_sponsor":"Baylor College of Medicine","biomarkers":" KIT • WT1 • CD33 • ANPEP","pipe":"","alterations":" ","tags":["KIT • WT1 • CD33 • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MultiTAA T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-06-19"},{"id":"68b4f52e-1dcf-41a8-96f4-f19ebb8b9a74","acronym":"","url":"https://clinicaltrials.gov/study/NCT02405338","created_at":"2021-01-18T11:29:06.551Z","updated_at":"2024-07-02T16:36:43.521Z","phase":"Phase 1/2","brief_title":"DC Vaccination for Post-remission Therapy in AML","source_id_and_acronym":"NCT02405338","lead_sponsor":"Medigene AG","biomarkers":" WT1 • PRAME","pipe":"","alterations":" ","tags":["WT1 • PRAME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CVT-DC-01"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2020-07-07"}]